

S/N 09/628,568

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: PRESTA ET AL. Examiner: D. SAUNDERS
Serial No.: 09/628,568 Group Art Unit: 1644
Filed: JULY 31, 2000 Docket No.: 11669.161USC1
Title: ALTERED POLYPEPTIDES WITH INCREASED HALF-LIFE

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV408489325US

Date of Deposit: November 17, 2004

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: 

Name: David Ortiz

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

23552
PATENT TRADEMARK OFFICE

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.


Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: November 17, 2004


Katherine M. Kowalchuk
Reg. No. 36,848
KMK:GJG:PLSkaw

FORM 1449*  INFORMATION DISCLOSURE STATEMENT ON AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.161USC1	Application Number: 09/628,568
	Applicant: PRESTA ET AL.	
	Filing Date: 07/31/2000	Group Art Unit: 1644

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Archelos, J. et al., "Inhibition of Experimental Autoimmune Neuritis by an Antibody to the Lymphocyte Function-Associated Antigen-1," <i>Laboratory Investigation</i> , Vol. 70, No. 5, pp. 667-675 (May 1994)					
		Connolly, M. et al., "Treatment of Murine Lupus with Monoclonal Antibodies to Lymphocyte Function-Associated Antigen-1: Dose-Dependent Inhibition of Autoantibody Production and Blockade of the Immune Response to Therapy," <i>Clinical Immunology and Immunopathology</i> , Vol. 72, No. 2, pp. 198-203 (August 1994)					
		Hasegawa, Y. et al., "Prevention of autoimmune insulin-dependent diabetes in non-obese diabetic mice by anti-LFA-1 and anti-ICAM-1 mAb," <i>International Immunology</i> , Vol. 6, No. 6, pp. 831-838 (1994)					
		Herold, K. et al., "Prevention of Autoimmune Diabetes by Treatment with Anti-LFA-1 and Anti-ICAM-1 Monoclonal Antibodies," <i>Cellular Immunology</i> , Vol. 157, No. 2, pp. 489-500 (September 1994)					
		Kawamura, O., "Antinephritic effect of anti-ICAM-1 monoclonal antibody and anti-LFA-1 monoclonal antibody on accelerated-type anti-GBM nephritis in rats," <i>The Japanese Journal of Nephrology</i> , Vol. 36, No. 2, pp. 103-112 (February 1994)					
		Laberge, S. et al., "Role of VLA-4 and LFA-1 in Allergen-Induced Airway Hyperresponsiveness and Lung Inflammation in the Rat," <i>American Journal of Respiratory and Critical Care Medicine</i> , Vol. 151, No. 3, pp. 822-829 (March 1995)					
		Matsuo, Y. et al., "Role of cell adhesion molecules in brain injury after transient middle cerebral artery occlusion in the rat," <i>Brain Research</i> , Vol. 656, No. 2, pp. 344-352 (September 12, 1994)					
		Nakao, Y. et al., "Monoclonal Antibodies Against ICAM-1 and LFA-1 Prolong Nerve Allograft Survival," <i>Muscle & Nerve</i> , Vol. 18, No. 1, pp. 93-102 (January 1995)					
		Tamiya, Y. et al., "Protective effect of monoclonal antibodies against LFA-1 and ICAM-1 on myocardial reperfusion injury following global ischemia in rat hearts," <i>Immunopharmacology</i> , Vol. 29, No. 1 pp. 53-63 (February 1995)					
		Tanaka, Y. et al., "Inhibition of Inflammatory Liver Injury by a Monoclonal Antibody against Lymphocyte Function-Associated Antigen-1," <i>The Journal of Immunology</i> , Vol. 151, No. 9, pp. 5088-5095 (November 1, 1993)					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	



FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.161USC1	Application Number: 09/628,568
	Applicant: PRESTA ET AL.	
	Filing Date: 07/31/2000	Group Art Unit: 1644

		Uchio, E. et al., "Suppression of Experimental Uveitis With Monoclonal Antibodies to ICAM-1 and LFA-1," <i>Investigative Ophthalmology & Visual Science</i> , Vol. 35, No. 5, pp. 2626-2631 (April 1994)
		Zahalka, M. et al., "Blocking Lymphoma Invasiveness with a Monoclonal Antibody Directed against the β -Chain of the Leukocyte Adhesion Molecule (CD18)," <i>The Journal of Immunology</i> , Vol. 150, No. 10, pp. 4466-4477 (May 15, 1993)

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	